NVRO vs. ANIK, SKIN, NPCE, OSUR, PLSE, SRDX, CVRX, TCMD, GUTS, and BVS
Should you be buying Nevro stock or one of its competitors? The main competitors of Nevro include Anika Therapeutics (ANIK), Beauty Health (SKIN), NeuroPace (NPCE), OraSure Technologies (OSUR), Pulse Biosciences (PLSE), Surmodics (SRDX), CVRx (CVRX), Tactile Systems Technology (TCMD), Fractyl Health (GUTS), and Bioventus (BVS). These companies are all part of the "surgical & medical instruments" industry.
Nevro (NYSE:NVRO) and Anika Therapeutics (NASDAQ:ANIK) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, risk, profitability, media sentiment, valuation, community ranking and institutional ownership.
Nevro received 203 more outperform votes than Anika Therapeutics when rated by MarketBeat users. Likewise, 65.84% of users gave Nevro an outperform vote while only 64.38% of users gave Anika Therapeutics an outperform vote.
Nevro has a beta of 0.96, indicating that its share price is 4% less volatile than the S&P 500. Comparatively, Anika Therapeutics has a beta of 0.74, indicating that its share price is 26% less volatile than the S&P 500.
95.5% of Nevro shares are owned by institutional investors. Comparatively, 91.5% of Anika Therapeutics shares are owned by institutional investors. 3.2% of Nevro shares are owned by insiders. Comparatively, 5.9% of Anika Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Nevro has a net margin of -21.69% compared to Anika Therapeutics' net margin of -49.60%. Anika Therapeutics' return on equity of -2.10% beat Nevro's return on equity.
Anika Therapeutics has lower revenue, but higher earnings than Nevro. Anika Therapeutics is trading at a lower price-to-earnings ratio than Nevro, indicating that it is currently the more affordable of the two stocks.
Nevro presently has a consensus target price of $20.00, suggesting a potential upside of 90.11%. Anika Therapeutics has a consensus target price of $29.50, suggesting a potential upside of 16.79%. Given Nevro's higher possible upside, analysts clearly believe Nevro is more favorable than Anika Therapeutics.
In the previous week, Nevro had 3 more articles in the media than Anika Therapeutics. MarketBeat recorded 18 mentions for Nevro and 15 mentions for Anika Therapeutics. Anika Therapeutics' average media sentiment score of 0.24 beat Nevro's score of 0.20 indicating that Anika Therapeutics is being referred to more favorably in the news media.
Summary
Nevro beats Anika Therapeutics on 10 of the 17 factors compared between the two stocks.
Get Nevro News Delivered to You Automatically
Sign up to receive the latest news and ratings for NVRO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding NVRO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
